TY - JOUR
KW - Acute Disease
KW - Antidepressive Agents/therapeutic use
KW - Data Collection
KW - Depressive Disorder, Major/economics/psychology/therapy
KW - England
KW - Germany
KW - Guideline Adherence
KW - Health Care Costs/statistics & numerical data
KW - Humans
KW - Primary Health Care/economics/statistics & numerical data
KW - Psychotherapy
KW - Quality Assurance, Health Care/economics
KW - Retrospective Studies
KW - Switzerland
AU - A. Gandjour
AU - A. Telzerow
AU - K. W. Lauterbach
AU - INTERCARE International Investigators
A1 - 
AB - No study has yet compared the costs and quality of depression treatment between European countries. The present study aimed to compare the costs and quality of treatment for the first manifestation of an acute major depression in England, Germany and Switzerland. Seventy-four randomly selected physician practices assessed their services for one hypothetical average patient (cost evaluation) and 73 practices reported retrospective data on one real patient (quality evaluation) for the year 2001. Reimbursement fees served as unit costs for Germany and Switzerland. Average reimbursement fees were used to measure resource utilization in all countries. Resource utilization was lowest in Switzerland. The percentage of patients receiving evidence-based treatment for major depression was insignificantly higher in Switzerland and England compared to Germany (56%, 52% and 35%, respectively; P>0.30). Switzerland was both the most effective and the most efficient country (in terms of resource utilization) in providing outpatient treatment for depression.
BT - International clinical psychopharmacology
C5 - Financing & Sustainability
CP - 4
CY - England
IS - 4
JF - International clinical psychopharmacology
N2 - No study has yet compared the costs and quality of depression treatment between European countries. The present study aimed to compare the costs and quality of treatment for the first manifestation of an acute major depression in England, Germany and Switzerland. Seventy-four randomly selected physician practices assessed their services for one hypothetical average patient (cost evaluation) and 73 practices reported retrospective data on one real patient (quality evaluation) for the year 2001. Reimbursement fees served as unit costs for Germany and Switzerland. Average reimbursement fees were used to measure resource utilization in all countries. Resource utilization was lowest in Switzerland. The percentage of patients receiving evidence-based treatment for major depression was insignificantly higher in Switzerland and England compared to Germany (56%, 52% and 35%, respectively; P>0.30). Switzerland was both the most effective and the most efficient country (in terms of resource utilization) in providing outpatient treatment for depression.
PP - England
PY - 2004
SN - 0268-1315; 0268-1315
SP - 201
EP - 208
EP - 
T1 - Costs and quality in the treatment of acute depression in primary care: A comparison between England, Germany and Switzerland
T2 - International clinical psychopharmacology
TI - Costs and quality in the treatment of acute depression in primary care: A comparison between England, Germany and Switzerland
U1 - Financing & Sustainability
U2 - 15201566
VL - 19
VO - 0268-1315; 0268-1315
Y1 - 2004
ER -